| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:519.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
From Cardiovascular Genetics Research, University of Utah, Salt Lake City, UT (P.N.H., S.C.H.); Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC (G.H.); Boston University School of Medicine, Boston, MA (R.C.E.); Division of Biostatistics, Washington University, St Louis, Mo (M.A.P.); Division of Epidemiology, School of Public Health (J.S.P.), and Department of Laboratory Medicine and Pathology (J.H.E.), University of Minnesota, Minneapolis, Minn.
Correspondence to Paul N. Hopkins, MD, MSPH, Cardiovascular Genetics, 410 Chipeta Way, Room 167, Salt Lake City, UT 84108. E-mail paul{at}ucvg.med.utah.edu
Received December 17, 2002; de novo received March 3, 2003; revision received May 9, 2003; accepted May 12, 2003.
Background Conventional wisdom suggests that a diagnosis of familial combined hyperlipidemia (FCHL) carries a substantially greater risk of premature coronary artery disease (CAD) than a diagnosis of familial hypertriglyceridemia (FHTG). However, no population-based studies have critically addressed this issue.
Methods and Results FCHL and FHTG were diagnosed in 10.2% and 12.3% of 334 random control families and in 16.7% and 20.5% of 293 families with at least one case of premature CAD. The diagnosis of either FCHL or FHTG in an individual was associated with an odds ratio for CAD of 2.0 (P=0.003 and 0.002, respectively). However, odds ratios for premature CAD associated with both lipid disorders decreased substantially and identically with further adjustment for hypertension, diabetes, and especially HDL cholesterol, triglycerides, or apolipoprotein B. Similar results were found for differences in carotid intima-medial thickness and ankle-brachial index. Metabolic syndrome was identified in 65% of FCHL and 71% of FHTG patients compared with 19% in controls without FCHL or FHTG and was associated with an odds ratio of 3.3 (P<0.0001). The increased prevalence of the metabolic syndrome alone could account for the elevated CAD risk associated with both FCHL and FHTG.
Conclusions FCHL and FHTG appear more alike than dissimilar. Further, the risk of CAD in FCHL and FHTG was strongly related to features of the metabolic syndrome. These findings suggest that the hypertriglyceridemia in FHTG is not benign and may warrant a change in epidemiological, genetic, and clinical approaches to these lipid disorders.
Key Words: coronary disease genetics lipoproteins epidemiology
This article has been cited by other articles:
![]() |
M. Solanas-Barca, R. Mateo-Gallego, P. Calmarza, E. Jarauta, A. M. Bea, A. Cenarro, and F. Civeira Mutations in HFE Causing Hemochromatosis Are Associated with Primary Hypertriglyceridemia J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4391 - 4397. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Wiesbauer, H. Blessberger, D. Azar, G. Goliasch, O. Wagner, L. Gerhold, K. Huber, K. Widhalm, F. Abdolvahab, G. Sodeck, et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (<=40 years of age) Eur. Heart J., May 1, 2009; 30(9): 1073 - 1079. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Horswell, H. E. Ringham, and C. C. Shoulders New technologies for delineating and characterizing the lipid exome: prospects for understanding familial combined hyperlipidemia J. Lipid Res., April 1, 2009; 50(Supplement): S370 - S375. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mukherjee, K. T. Locke, B. Miao, D. Meyers, H. Monshizadegan, R. Zhang, D. Search, D. Grimm, M. Flynn, K. M. O'Malley, et al. Novel Peroxisome Proliferator-Activated Receptor {alpha} Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 716 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Ferns, V Keti, and B Griffin Investigation and management of hypertriglyceridaemia J. Clin. Pathol., November 1, 2008; 61(11): 1174 - 1183. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Dickson, X. Tian, X. Liu, D. R. Davis, and C. D. Sigmund Upstream Stimulatory Factor Is Required for Human Angiotensinogen Expression and Differential Regulation by the A-20C Polymorphism Circ. Res., October 24, 2008; 103(9): 940 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Seidelmann, L. Li, G.-Q. Shen, E. J. Topol, and Q. K. Wang Identification of a novel locus for triglyceride on chromosome 1p31-32 in families with premature CAD and MI J. Lipid Res., May 1, 2008; 49(5): 1034 - 1038. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Juonala, J. S.A. Viikari, T. Ronnemaa, J. Marniemi, A. Jula, B.-M. Loo, and O. T. Raitakari Associations of Dyslipidemias From Childhood to Adulthood With Carotid Intima-Media Thickness, Elasticity, and Brachial Flow-Mediated Dilatation in Adulthood: The Cardiovascular Risk in Young Finns Study Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 1012 - 1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Naoumova, H. Kindler, L. Leccisotti, M. Mongillo, M. T. Khan, C. Neuwirth, M. Seed, P. Holvoet, J. Betteridge, and P. G. Camici Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Study J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2051 - 2058. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Brunzell Hypertriglyceridemia N. Engl. J. Med., September 6, 2007; 357(10): 1009 - 1017. [Full Text] [PDF] |
||||
![]() |
S. Qu, G. Perdomo, D. Su, F. M. D'Souza, N. S. Shachter, and H. H. Dong Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice J. Lipid Res., July 1, 2007; 48(7): 1476 - 1487. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. de Graaf, G. M. van der Vleuten, E. ter Avest, G. M. Dallinga-Thie, and A. F. H. Stalenhoef High Plasma Level of Remnant-Like Particles Cholesterol in Familial Combined Hyperlipidemia J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1269 - 1275. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Dickson, M. B. Zimmerman, K. Rahmouni, and C. D. Sigmund The -20 and -217 Promoter Variants Dominate Differential Angiotensinogen Haplotype Regulation in Angiotensinogen-Expressing Cells Hypertension, March 1, 2007; 49(3): 631 - 639. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yu, D. F. Wyszynski, D. M. Waterworth, S. D. Wilton, P. J. Barter, Y. A. Kesaniemi, R. W. Mahley, R. McPherson, G. Waeber, T. P. Bersot, et al. Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia J. Lipid Res., October 1, 2005; 46(10): 2202 - 2213. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Naukkarinen, M. Gentile, A. Soro-Paavonen, J. Saarela, H. A. Koistinen, P. Pajukanta, M.-R. Taskinen, and L. Peltonen USF1 and dyslipidemias: converging evidence for a functional intronic variant Hum. Mol. Genet., September 1, 2005; 14(17): 2595 - 2605. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Hopkins, L. L. Wu, S. C. Hunt, and E. A. Brinton Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1003 - 1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-D. Li, C. Dong, D. Li, C. Garrigan, and R. A. Price A genome scan for serum triglyceride in obese nuclear families J. Lipid Res., March 1, 2005; 46(3): 432 - 438. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Morello, T. W.A. de Bruin, J. I. Rotter, R. E. Pratt, C. J.H. van der Kallen, G. A. Hladik, V. J. Dzau, C.-C. Liew, and Y.-D. I. Chen Differential Gene Expression of Blood-Derived Cell Lines in Familial Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 2149 - 2154. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Carr and J. D. Brunzell Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2601 - 2607. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.C. Shoulders, E.L. Jones, and R.P. Naoumova Genetics of familial combined hyperlipidemia and risk of coronary heart disease Hum. Mol. Genet., April 1, 2004; 13(90001): R149 - 160. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |